Laney McGowan, the young Sayville girl who inspired others through her yearslong battle with severe epilepsy, has died at the ...

Detailed price information for Stoke Therapeutics Inc (STOK-Q) from The Globe and Mail including charting and trades.

In June, the U.S. Food and Drug Administration approved the medication fenfluramine for people with severe epilepsy and Dravet syndrome, or SCN1A-related seizure disorders, who are 2 years of age or ...

Dravet syndrome is a type of epilepsy that starts during a child's first year. If your child has this condition, they might have seizures that last for several minutes at a time. In their first few ...

– Data from the positive interim analysis of the Phase 1/2a MONARCH study of STK-001 in children and adolescents with Dravet syndrome will be presented – “At Stoke, our goal is to develop the first ...

UCB wants you to hear the sound of profound seizure reduction. Across a series of videos, the Belgian drugmaker makes the case that its Dravet syndrome drug Fintepla amplifies family life by allowing ...

Dravet syndrome can affect sleep quality as well as other factors not directly related to epilepsy. Certain medications may be to blame for sleep disturbances in patients with DS. Poor sleep quality ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Participants given STK-001 in one dose experienced a 43% ...

Zogenix, Inc. ZGNX announced that the FDA has approved Fintepla (fenfluramine) oral solution, CIV for the treatment of seizures associated with DravetSyndrome in patients 2 years of age or older. The ...

To date, ETX101 has shown a favorable safety profile and has been well-tolerated across all four dose levels with no treatment-related serious adverse events (n=19). The most common treatment-related ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression ...